Please use this identifier to cite or link to this item:
|Title:||An update on targeting Hippo-YAP signaling in liver cancer|
|Authors:||Liu, A.M. |
|Citation:||Liu, A.M., Xu, Z., Luk, J.M. (2012-03). An update on targeting Hippo-YAP signaling in liver cancer. Expert Opinion on Therapeutic Targets 16 (3) : 243-247. ScholarBank@NUS Repository. https://doi.org/10.1517/14728222.2012.662958|
|Abstract:||Hepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd.|
|Source Title:||Expert Opinion on Therapeutic Targets|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 19, 2018
WEB OF SCIENCETM
checked on Jun 11, 2018
checked on Apr 20, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.